Gene therapy

The Hospital for Sick Children (SickKids) in Toronto, Canada
#Gene therapy #Genetics / genomics #Neurodegenerative disorders #Rare disease

Gene therapy halts progression of rare genetic condition

The findings from a single-patient gene therapy trial in Canada show promise in halting the progression of spastic paraplegia type 50 (SPG50). SPG50 is an ultra-rare progressive neurodegenerative disorder that causes developmental delays, speech impairment, seizures, progressive paralysis of all four limbs, and is typically fatal… Read More

#News #Trending News

Cell and gene therapies
#AskBio #Gene therapy #Neurodegenerative disorders #Parkinson's #Phase II trial

Gene therapy for Parkinson’s disease progresses to Phase II

A new Phase II trial, REGENERATE-PD, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of moderate-stage Parkinson’s disease. The trial will include an estimated 87 subjects with study sites located in the US, UK and… Read More

#News

#EG 427 #Gene therapy #Neurology #Phase II trial

First gene therapy for bladder condition enters clinical study

Biotechnology company EG 427 has revealed plans to start a Phase Ib/IIa clinical study in neurogenic detrusor overactivity (NDO), following Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA). NDO is a severe bladder condition affecting patients living with spinal cord injury,… Read More

#News

FDA headquarters
#Duchenne muscular dystrophy #FDA #Gene therapy #Roche #Sarepta Therapeutics

FDA expands gene therapy use in Duchenne muscular dystrophy

The US Food and Drug Administration (FDA) has expanded its approval for Elevidys (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are at least four years of age. Confirming the functional benefits, the FDA granted traditional approval for ambulatory… Read More

#News #Regulatory

Melanoma or skin cancer
#Dermatology #Francis Crick Institute #Gene therapy #Great Ormond Street Hospital #Melanoma #RNA

Silencing RNA causes moles to self-destruct in rare condition

UK researchers have designed a new genetic therapy that could alleviate debilitating giant moles in a rare skin condition. The treatment could be used to reverse moles, and therefore prevent cancer. It could also potentially reverse other types of at-risk moles as an alternative to surgery. Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Genetics / genomics

New DDW Highlights podcast: 17 June 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With a lead story on the restoration of congenital hearing loss following gene therapy,… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Genetics / genomics

This week in drug discovery (10-14 June) 

News round-up for 10-14 June by DDW Senior Digital Content Editor Diana Spencer. With a lead story on the restoration of congenital hearing loss following gene therapy, the news highlights selection this week focuses on cell and gene therapies (CGT) and genetics, particularly some key progress in relation… Read More

#News

Gene therapy
#Clinical trial #Gene therapy #Genetics / genomics #Hearing Loss #Paediatrics #Regeneron Pharmaceuticals

Gene therapy restores hearing in both ears

Five children who were born with congenital hearing loss can hear in both ears after taking part in a gene therapy trial at Fudan University in Shanghai, China. Within weeks of receiving the therapy, the children could locate the sources of sounds, and recognised speech in… Read More

#News

#Cardiovascular disease #Cell and gene therapy #Cell therapy #circular RNAs #Gene therapy

New DDW Highlights podcast: 21 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  From a weight loss drug that prevents heart attacks and a gene therapy that… Read More

#News

#Cardiovascular disease #Cell and gene therapy #Cell therapy #circular RNAs #Gene therapy

This week in drug discovery (13-16 May) 

News round-up for 13-16 May by DDW Senior Digital Content Editor Diana Spencer. From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent… Read More

#News

RNA strand
#Circio Holding #circular RNAs #Gene therapy #Genetic diseases #In vivo #mRNA

Data demonstrates superiority of circular RNA vs linear mRNA

In vivo proof-of-concept for Circio Holding’s differentiated circVec platform approach to gene therapy has been demonstrated in two posters at the American Society of Gene & Cell Therapy (ASGCT) 2024 annual meeting. The in vivo data showed statistically significant higher expression level and durability for circVec… Read More

#News

Child having a hearing test
#Gene mutation #Gene therapy #Genetic diseases #Hearing Loss #Paediatrics #Rare disease

Gene therapy cures profound genetic deafness within 24 weeks

The investigational gene therapy DB-OTO improved hearing to normal levels in a child (dosed at 11 months of age) within 24 weeks, according to trial data presented at the American Society of Gene and Cell Therapy (ASGCT) annual conference. Initial hearing improvements have also been observed… Read More

#News #Trending News

#AAV #Gene therapy #Genetics / genomics #Genome sequencing #Recombinant DNA #Webinar

How can long-read nanopore sequencing support gene therapy delivery?

Join DDW for this exclusive free event, ‘rAAV genome sequencing with Oxford Nanopore uncovers transgene integrity and packaging impurities’. The event will be supported by Oxford Nanopore Technologies. The event will feature experts Daniel Jachimowicz, Senior Bioscience Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden,… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#AAV #Gene therapy #Genetics / genomics #Genome sequencing #Recombinant DNA #Webinar

Uncovering packaging impurities with rAAV genome sequencing

Join DDW for this exclusive free event, ‘rAAV genome sequencing with Oxford Nanopore uncovers transgene integrity and packaging impurities’. The event will be supported by Oxford Nanopore Technologies. The event will feature experts Daniel Jachimowicz, Senior Bioscience Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden,… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Gene sequence
#AAV #Gene therapy #Genetics / genomics #Genome sequencing #Recombinant DNA

How rAAV genome sequencing uncovers transgene integrity

Join DDW for this exclusive free event, ‘rAAV genome sequencing with Oxford Nanopore uncovers transgene integrity and packaging impurities’. The event will be supported by Oxford Nanopore Technologies. The event will feature experts Daniel Jachimowicz, Senior Bioscience Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden,… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Parkinson's disease
#AskBio #Cell and gene therapy #Gene therapy #Neurodegenerative disorders #Parkinson's #Phase II trial

Gene therapy proved to be safe in patients with Parkinson’s disease

Askbio’s AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the treatment of Parkinson’s disease, was well tolerated with no serious adverse events in a Phase Ib clinical trial. The data were presented at the American Academy of Neurology 2024 Annual Meeting in Denver, Colorado,… Read More

#News #Trending News